Clinical Chemistry Route for Investigation of Alzheimer's Disease: A Label-Free Electrochemiluminescent Biosensor for Glycogen Synthase Kinase-3 Beta

Assembled Photonic Crystal/Gold Nanoparticle Interface: A Dual Amplifying Electrochemiluminescent Aptasensor for the Ultrasensitive Detection of an Amyloid-β Monomer

Amyloid-β (Aβ) protein is considered to be a key biomarker that is closely associated with Alzheimer's disease (AD). The level of Aβ, particularly its subtle fluctuation, indicates early neuropathological changes, which poses a considerable challenge in predicting AD, considering the detection limit of sensing technologies. Herein, a new label-free sensor based on luminol electrochemiluminescence (ECL) was proposed by developing a close-packed monolayered-SiO2 array with gold (Au) nanoparticles (NPs) entrapped in their gaps as the basal electrode. The well-organized SiO2 NPs with a quasiphotonic crystal structure amplified the ECL signal via light scattering, while Au NPs amplified the signal by directly catalyzing luminol oxidation. Owing to the dual signal amplification, the proposed electrode furnished an ∼64-fold-intensified ECL signal of luminol as the sensing background. Further, the as-prepared ECL electrode served as the substrate to develop an aptasensor for the sensitive detection of Aβ. The inhibition of the ECL signal due to the suppressed diffusion of luminol to the sensor surface acts as an indicator to quantify the amount of Aβ. The transfer dynamics mechanism provides a label-free sensing strategy and facilitates the high sensitivity of the aptasensor for Aβ detection. Under optimal conditions, the developed aptasensor exhibits an ultrasensitive performance for Aβ with a very low limit of detection of 5 fM, providing a new prospect for clinical research on Aβ and a promising approach in the field of ECL sensing.